Pancreatic cancer is staged from 0 to IV, with each stage reflecting how large the tumor has grown, whether it has reached nearby lymph nodes, and whether it has spread to distant organs. The stage at diagnosis is the single biggest factor in determining treatment options and outlook. Most pancreatic cancers are a type called ductal adenocarcinoma, and the staging system below applies to that form.
How Staging Works
Doctors use a system called TNM to classify pancreatic cancer. “T” describes the size and extent of the primary tumor, “N” indicates whether cancer has reached nearby lymph nodes, and “M” records whether it has spread (metastasized) to distant parts of the body. These three factors combine to assign an overall stage number.
CT scans are the primary tool for staging. They detect tumors with a sensitivity of 76 to 96 percent, and they predict whether a tumor can be surgically removed with an accuracy of roughly 73 to 87 percent. MRI performs similarly for detection but is generally reserved for patients who can’t tolerate CT contrast dye. PET/CT scans are sometimes added when doctors suspect the cancer may have already spread, particularly in patients with large tumors or very high levels of the blood marker CA 19-9.
Stage 0: Precancerous Changes
Stage 0, also called carcinoma in situ, means abnormal cells are confined to the innermost lining of the pancreatic duct. These cells have not invaded deeper tissue and have not spread anywhere. Stage 0 is rarely caught on its own because it causes no symptoms; it’s typically discovered incidentally during imaging or surgery for another condition. When it is found, removal of the affected tissue can prevent progression to invasive cancer.
Stage I: Small, Contained Tumors
At stage I, a true cancer has formed but remains entirely within the pancreas, with no lymph node involvement and no distant spread.
- Stage IA: The tumor is 2 centimeters or smaller, roughly the size of a peanut.
- Stage IB: The tumor is larger than 2 centimeters but no bigger than 4 centimeters.
Stage I tumors are considered resectable, meaning surgery to remove them is possible and offers the best chance of long-term survival. The five-year relative survival rate for localized pancreatic cancer (which includes stages I and some stage II cases) is about 44 percent. That number has improved significantly over the past decade. After surgery, nearly all patients receive additional chemotherapy to reduce the risk of the cancer returning.
Stage II: Larger Tumors or Nearby Lymph Nodes
Stage II covers two scenarios. The tumor may have grown larger than 4 centimeters while still confined to the pancreas, or a smaller tumor may have spread to one to three nearby lymph nodes. In either case, the cancer has not reached distant organs.
Many stage II tumors are still surgically removable. The operation depends on where the tumor sits. Tumors in the head of the pancreas (the most common location) typically require removal of the head of the pancreas along with part of the small intestine and bile duct. Tumors in the body or tail require removal of that section, often along with the spleen. After surgery, chemotherapy follows to target any microscopic cancer cells left behind.
Stage III: Locally Advanced Disease
Stage III means the cancer has grown into major blood vessels near the pancreas or has spread to four or more regional lymph nodes, but it has not reached distant organs. This is where the concept of resectability becomes critical, and it often matters more than the stage number itself.
Doctors classify locally advanced tumors into practical categories based on CT imaging:
- Borderline resectable: The tumor touches or partially surrounds a major artery or vein. These patients typically receive chemotherapy first (sometimes with radiation) to shrink the tumor before surgery is attempted.
- Locally advanced type A: The tumor completely surrounds certain blood vessels, but surgery may still become possible after an aggressive course of chemotherapy and radiation.
- Locally advanced type B: The tumor wraps around blood vessels in a way that makes surgical removal essentially impossible regardless of treatment response.
For patients whose tumors cannot be removed, the goal of treatment shifts to controlling the cancer’s growth and managing symptoms. Chemotherapy is the backbone of treatment. Radiation is sometimes added for patients whose cancer stays localized (doesn’t spread to distant sites) after several months of chemotherapy. The five-year survival rate for regional-stage pancreatic cancer is about 17 percent.
Stage IV: Cancer Has Spread to Distant Organs
Stage IV pancreatic cancer has metastasized to organs beyond the pancreas and its immediate surroundings. The liver is the most common site, followed by the lungs, the lining of the abdominal cavity (peritoneum), and bones. Less frequently, it spreads to the adrenal glands or brain.
Surgery to remove the primary tumor is not standard at this stage because the disease is already systemic. Treatment focuses on chemotherapy to slow progression and supportive care to manage pain, digestive problems, and weight loss. The choice of chemotherapy regimen depends largely on the patient’s overall health and functional status. Patients who are relatively strong may tolerate more intensive combination regimens, while those who are frailer receive gentler single-drug therapy.
The five-year relative survival rate for distant-stage pancreatic cancer is 3.4 percent. While that number is sobering, it represents an average across all patients, and individual outcomes vary based on factors like tumor biology, response to treatment, and overall health at diagnosis.
Why Early Detection Is So Difficult
One of the central challenges with pancreatic cancer is that the earliest, most treatable stages rarely produce noticeable symptoms. The pancreas sits deep in the abdomen, behind the stomach, so tumors can grow without causing pain or other obvious signs. By the time symptoms like jaundice, unexplained weight loss, new-onset diabetes, or persistent back pain appear, the cancer is often at stage III or IV. Roughly half of all pancreatic cancer cases are diagnosed after the disease has already spread to distant organs.
There is no widely recommended screening test for the general population. For people at high risk, such as those with a strong family history of pancreatic cancer or known genetic mutations (like BRCA2), specialized monitoring with MRI or endoscopic ultrasound may catch tumors at earlier, more treatable stages.
Neuroendocrine Tumors Are Staged Differently
About 5 to 10 percent of pancreatic cancers are neuroendocrine tumors, which arise from hormone-producing cells rather than the cells lining the pancreatic ducts. These tumors use a separate staging system. The size thresholds are similar (under 2 cm, 2 to 4 cm, over 4 cm), but the criteria for advanced disease differ. Neuroendocrine tumors that have spread are further subdivided: metastasis confined only to the liver is classified differently from spread to other organs like the lungs, bones, or peritoneum. Neuroendocrine pancreatic cancers generally grow more slowly and carry a better prognosis than ductal adenocarcinoma at the same stage, though aggressive forms exist.